2,294 results
P
Oral anticoagulants (OAC), P-glycoprotein (P-gp)/CYP3A4 enzyme
I/C
P-gp/CYP3A4 inhibitors, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Warfarin
O
Major bleeding, Gastrointestinal (GI) bleeding, Stroke/systemic embolism (SE), All-cause mortality, Any bleeding, Intracranial hemorrhage (ICH)
P
soil microbial extracellular hydrolytic enzymatic activities (Hy-EEAs), soil oxidative enzymatic activities (Ox-EEAs), soil carbon (C), soil nitrogen (N), soil phosphorus (P)
I/C
natural forest conversion (NFC), Changes in soil Hy- and Ox-EEAs, changes in soil organic C, available P, microbial biomass C and N
O
depletion of soil organic carbon, stimulated soil microbial secretion of Hy- and Ox-EEAs, soil total N scarcity, provoke soil microbial Hy-EEAs, soil total P dearth, quickened the soil Ox-EEAs, plenitude of soil available P, suppressed soil Hy- and Ox-EEAs
P
laying hens
I/C
coarse limestone particles, fine limestone particles
O
eggshell quality, bone strength, tibia breaking strength
P
NSCL/P patients, controls
I/C
MTHFR A1298C polymorphism, allele, homozygote, heterozygote, dominant, and recessive models
O
association between A1298C polymorphism and NSCL/P risk
P
patients with lesions within or adjacent to the digestive tract
I/C
EUS-FNB using a 22G needle, EUS-FNB using other needle sizes
O
diagnostic accuracy rate, technical success rate, adverse event rate
P
prostate cancer patients
I/C
high-dose-rate brachytherapy (HDR-BT) with external beam radiation therapy (EBRT), IDC-P and without IDC-P
O
oncological outcomes, including biochemical recurrence-free survival (BCRFS) and clinical progression-free survival (CPFS)
P
patients with cervical spondylotic myelopathy (CSM)
I/C
Zero profile intervertebral fusion system (Zero-P), traditional anterior plate cage system (PC)
O
postoperative dysphagia, avoiding ALOD, ASD, screw loosening
P
PD patients
I/C
Pramipexole (P) or levodopa (L) treatment, P+L combination therapy, L monotherapy
O
clinical efficacy, UPDRS scores, Hamilton depression rating scale score, adverse events
P
I/C
p-curve analysis, ERN and RewP literatures
O
evidential value for a relationship between each ERP and depression
P
East Asians
I/C
eNOS rs2070744 polymorphism, dominant comparison: OR = 0.77, p = .01; overdominant comparison: OR = 1.24, p = .04; allele comparison: OR = 0.78, p = .006
O
predisposition to hemorrhagic cerebral vascular diseases